Polyphenol-Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Cardiovascular Research

Background:

• Myocardial infarction is a major cause of death, with current treatments limited by inflammation and poor drug delivery.
• Restoring blood flow and oxygen supply is crucial, but inflammatory responses and inefficient drug delivery hinder functional recovery.
• Existing invasive procedures carry risks and may not effectively target infarcted heart regions.

Purpose of the Study:

• To develop a nanoengineered monocyte (MO)-based biohybrid system (CTAs@MOs) for targeted cardiac delivery of therapeutic agents.
• To overcome limitations of malperfusion and inflammation in infarcted myocardium.
• To evaluate the efficacy of CTAs@MOs in improving cardiac function and reducing infarct size.

Main Methods:

• A polyphenol-mediated interfacial assembly was used to create the CTAs@MOs system.
• Systemic administration of CTAs@MOs for heart-targeted delivery of anti-inflammatory IL-10 and cardiomyogenic miR-19a.
• Evaluation of cardiac function, inflammation modulation, and cardiomyocyte proliferation in infarcted hearts.

Main Results:

• CTAs@MOs demonstrated infarcted heart-specific accumulation and sustained release of therapeutic agents.
• The system effectively modulated the proinflammatory microenvironment and promoted cardiomyocyte proliferation.
• Significant improvements in cardiac function were observed, including enhanced ejection fraction, increased fractional shortening, and diminished infarct sizes.

Conclusions:

• The polyphenol nanoengineered MO-based biohybrid system (CTAs@MOs) is a potent platform for treating cardiovascular disorders.
• Systemic administration offers a safer alternative to invasive procedures, with targeted delivery to the infarcted myocardium.
• This approach shows promise for immunomodulation and promoting cardiac regeneration post-myocardial infarction.